SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
Innovative Science Overcomes Formulation Challenges
SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.
A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.
Partnering to Advance Therapy for Radiation Exposure
Partnering to Rapidly Advance ZMapp® for Ebola Treatment
For the National Institute of Mental Health (NIMH), SRI performs preclinical safety and pharmacokinetics studies for brain imaging agents and drugs to treat mental illnesses.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.